• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MannKind

< Previous 1 2 3 Next >
News headline image
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
May 01, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
April 07, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
March 10, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 26, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
February 19, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Present at Upcoming Investor Conferences
February 06, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Expands Executive Leadership Team
January 06, 2025
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
December 18, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
December 16, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
December 11, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
November 07, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Present at 2024 UBS Healthcare Conference
November 05, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
November 04, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
October 31, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
September 30, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
September 18, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
September 10, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Present at Upcoming Conferences
August 27, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
August 14, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
August 07, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
July 31, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
July 30, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 05, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
May 29, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
May 01, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
News headline image
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap